Xenon Pharmaceuticals Inc. (NASDAQ:XENE) is one of the 10 Stocks Making Huge Moves this Week. Xenon Pharmaceuticals climbed by 31.7 percent week-on-week, as investor sentiment was bolstered by ...

Xenon Pharmaceuticals shares rose after the company said it received positive data from its study of its investigational treatment for focal onset seizures. Shares rose 46.5% to $61.45. The ...

Xenon Pharmaceuticals Inc. stock has reached an all-time high, currently trading at $59.03. This milestone highlights the company’s robust performance in the market over the past year, though ...

Rick Bishop got a black Labrador named Sailor in 2017 to help deal with the epileptic seizures he had multiple times daily. Sailor hasn’t had much to do since the rural Pennsylvania-based retiree ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

Phase 3 X-TOLE2 topline data for azetukalner in FOS expected first half of March 2026 Five additional Phase 3 studies of azetukalner continue to enroll in epilepsy and neuropsychiatry indications with ...

Connecticut-based Braidwell sold 1,779,953 Xenon Pharmaceuticals shares in the fourth quarter; the estimated transaction value was $74.76 million based on quarterly average prices. Meanwhile, the ...

Threat actors are abusing Pastebin comments to distribute a new ClickFix-style attack that tricks cryptocurrency users into executing malicious JavaScript in their browser, allowing attackers to ...

The X-TOLE2 study has completed enrollment with 380 patients randomized. Additionally, Xenon is conducting five more Phase 3 studies for azetukalner in epilepsy and neuropsychiatric indications. In ...

Deadline’s Read the Screenplay series spotlighting the scripts behind the awards season’s most talked-about movies continues with Warner Bros‘ Weapons. Writer-director Zach Cregger described the ...